|
1) Ferrara F. Acute promyelocytic leukemia: what are the treatment options？ Expert Opin Pharmacother. 2010; 11: 587-96
|
|
|
|
2) Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009; 113: 1875-91
|
|
|
|
|
|
3) Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol. 1998; 16: 78-85
|
|
|
|
|
|
4) Asou N, Kishimoto Y, Kiyoi H, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL 97 study. Blood. 2007; 110: 59-66
|
|
|
|
|
|
5) Avvisati C, Petti MC, Lo Coco F, et al. GIMEMA (Gruppo Italiano Malattie Ematologiche dellʼAdulto) Italian Cooperative Group. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP0389 with 7 years of minimal follow-up. Blood. 2002; 100: 3141-6
|
|
|
|
|
|
6) Sanz MA, Martin G, Gonzalez M, et al. Risk-adopted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monotherapy: a multicenter study by the PETHEMA group. Blood. 2004; 103: 1237-43
|
|
|
|
|
|
7) Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999; 94: 1192-200
|
|
|
|
|
|
8) Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIEMEMA cooperative groups. Blood. 2000; 96: 1247-53
|
|
|
|
|
|
9) Adès L, Fenaux P. Is cytarabine required in the treatment of acute promyelocytic leukemia？ Update experience and review of the literature. Clin Adv Hematol Oncol. 2006; 4: 678-82
|
|
|
|
|
|
10) Zhang P. The use of arsenic trioxide(As2O3)in the treatment of acute promyelocytic leukemia. J Biol Regul Homeost Afents. 1999; 13: 195-200
|
|
|
|
|
|
11) Mathews V, Gerge B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remission with minimal toxicity. Blood. 2006; 107: 2627-32
|
|
|
|
|
|
12) Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006; 17: 131-4
|
|
|
|
|
|
13) Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009; 27: 504-10
|
|
|
|
|
|
14) Hu J, Liu F-Y, Wu C-F, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009; 106: 3342-7
|
|
|
|
|
|
15) Ades L, Chevret S, De Botton S, et al. Outcome of acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia. 2005; 19: 230-3
|
|
|
|
|
|
16) Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008; 35: 418-29
|
|
|
|
|
|
17) Sanz MA, Lo Coco F. Standard practice and controversial issues in front-line therapy of acute promyelocytic leukemia. Haematologica. 2005; 90: 840-5
|
|
|
|
|
|
18) Lo Coco F, Ammatuna E, Montesinos P, et al. Acute promyelocytic leukemia: recent advances in diagnosis and managements. Semin Oncol. 2008; 35: 401-9
|
|
|
|
|
|
19) Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA group. Blood. 2008; 112: 3130-34
|
|
|
|
|
|
20) Powell BL, Moser B, Stock W, et al. Effect of consolidation with arsenic trioxide(As2O3)on event free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. ASCO Meeting Abstract Part I. J Clin Oncol. 2007; 25: 2a
|
|
|
|
|
|
21) Avvisati G, Petti MC, Lo Coco F, et al. AIDA: the Italian way of treating acute promyelocytic leukemia (APL), final act. Blood. 2003; 102: 142a
|
|
|
|
|
|
22) Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. Blood. 1999; 94: 3015-21
|
|
|
|
|
|
23) Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Hematol. 2007; 20: 57-65
|
|
|
|
|
|
24) Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001; 19: 3852-60
|
|
|
|
|
|
25) Ferrara F, Palmieri S, Annunziata M, et al. Prolonged molecular remission after autologous stem cell transplantation in relapsed acute promyelocytic leukemia. Haematologica. 2004; 89: 621-2
|
|
|
|
|
|
26) Thirugnanam R, George B, Chendamarai E, et al. Comparison of clinical outcome of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant. 2009; 15: 1479-84
|
|
|
|
|
|
27) Linker CA, Owzar K, Powell B, et al. Auto-SCT for AML in second remission: CALGB Study 9620. Bone Marrow Transplant. 2009; 44: 353-9
|
|
|
|
|
|
28) Kharfan-Dabaja MA, Abou Mourad YR, Fernandez HF, et al. Hematopoietic cell transplantation in acute promyelocytic leukemia: a comprehensive review. Biol Blood Marrow Transplant. 2007; 13: 997-1004
|
|
|
|
|
|
29) Sanz MA, Labopin M, Gorin NC, et al. Acute Leukemia Working Party (ALWP) of European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2007; 39: 461-9
|
|
|
|
|
|
30) Nasr R, Guillemin MC, Ferhi O, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARΑ degradation. Nat Med. 2008; 14: 1333-42
|
|
|
|
|
|
31) Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009; 113: 775-83
|
|
|
|
|
|
32) Luesink M, Pennings JL, Wisssink WM, et al. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia-triggering the differentiation syndrome. Blood. 2009; 114: 5512-21
|
|
|
|
|
|
33) Cunha De Santis G, Tamarozzi MB, Sousa RB, et al. Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. Haematologica. 2007; 92: 1615-22
|
|
|
|
|